Back to News
Market Impact: 0.2
Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & Outlook
Lyell Immunopharma expects pivotal data in mid-2027 for ronde-cel, its lead CAR-T therapy. The treatment is being advanced for patients with large B-cell lymphoma who have received at least two prior lines of therapy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
LYEL0.10
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Soaring freight rates give US refiners edge as crude discounts widen
- Axon Enterprise earnings analysis: questions answered and next catalysts
- Investing in Prediction Markets Will Pay Off, DraftKings CEO Says